Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data

Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.

Diagnosis of Multiple Myeloma. Test tubes or bottles for blood, stethoscope and laboratory hematology analysis surrounded by text title of diagnosis of Multiple Myeloma lie in the doctor workplace
Ixazomib Positive In Multiple Myeloma Maintenance • Source: Shutterstock

Single-agent Ninlaro (ixazomib) as maintenance therapy in multiple myeloma following autologous stem cell transplant (ASCT) reduced the risk of disease progression or death by around a third versus placebo, new data from a major study with the Takeda Pharmaceutical Co. Ltd. drug show.

Detailed data from the TOURMALINE-MM3 trial presented to the 60th American Society of Hematology (ASH) meeting in San Diego should...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category